CANDEL THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
CANDEL THERAPEUTICS, INC. (CADL) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 28.69 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-12
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 28.69M shares, a 146.32% increase year-over-year.
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 28.75M shares, a 147.52% increase year-over-year.
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 23.33M shares, a 100.83% increase year-over-year.
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 11.72M shares, a 0.91% increase year-over-year.
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 18.87M shares, a 62.49% increase from fiscal 2020.
- CANDEL THERAPEUTICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 11.62M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | 28.69M shares 10-Q · filed 2022-05-12 | 28.72M shares derived: average of 2 quarters · filed 2022-05-12 | 26.92M shares derived: average of 3 quarters · filed 2022-05-12 | 23.12M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 28.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 26.04M shares derived: average of 2 quarters · filed 2022-03-29 | 21.27M shares derived: average of 3 quarters · filed 2022-03-29 | 18.87M shares 10-K · filed 2022-03-29 |
| 2021-09-30 | 23.33M shares 10-Q · filed 2021-11-12 | 17.52M shares derived: average of 2 quarters · filed 2021-11-12 | 15.58M shares 10-Q · filed 2021-11-12 | 14.58M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-06-30 | 11.72M shares 10-Q · filed 2021-09-08 | 11.68M shares 10-Q · filed 2021-09-08 | 11.66M shares derived: average of 3 quarters · filed 2022-05-12 | 11.65M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | 11.65M shares 10-Q · filed 2022-05-12 | 11.63M shares derived: average of 2 quarters · filed 2022-05-12 | 11.63M shares derived: average of 3 quarters · filed 2022-05-12 | 11.62M shares derived: average of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | 11.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 11.62M shares derived: average of 2 quarters · filed 2022-03-29 | 11.62M shares derived: average of 3 quarters · filed 2022-03-29 | 11.62M shares 10-K · filed 2022-03-29 |
| 2020-09-30 | 11.61M shares 10-Q · filed 2021-11-12 | 11.61M shares derived: average of 2 quarters · filed 2021-11-12 | 11.61M shares 10-Q · filed 2021-11-12 | |
| 2020-06-30 | 11.61M shares 10-Q · filed 2021-09-08 | 11.61M shares 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |